| Patient | Frida Kahlo |
|---|---|
| Date of birth | 1989-07-06 |
| Identifiers | MRN HR-NI011-SYN; SSN (made up) 000-11-4390 |
| Document date | 2026-10-15 |
| Author | Marisol Ortega, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Four-week chronic pain follow-up and first opioid dose reduction. [S]
Ms. Kahlo returns four weeks after her first visit. The cold she had last week has cleared. She has gone to physical therapy twice a week, missing one aquatic session while she was ill, and wears the new shoe lift. On duloxetine 60 mg for two weeks she has had no nausea, sweating, or dizziness. The burning in her right leg is less, and she now stands at the easel for about 20 minutes. She has kept to no more than four oxycodone tablets a day and on most days takes three or four. She is ready for the first dose reduction she agreed to two weeks ago, and she starts weekly cognitive behavioral therapy for chronic pain today. [S]
| Element | Detail |
|---|---|
| Recent illness | Common cold last week, cleared |
| Rehabilitation | Physical therapy twice weekly; one session missed while ill; shoe lift in use |
| Duloxetine 60 mg | Two weeks, no side effects |
| Function | Stands at the easel for about 20 minutes |
| Opioid use | Three or four oxycodone tablets on most days; never more than four |
| Taper | Ready for the agreed first reduction |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or drowsiness |
| Respiratory | Negative | Cough gone |
| Gastrointestinal | Negative | No nausea or constipation |
| Musculoskeletal | Positive | Back and pelvic pain, easing; right ankle pain on standing; no falls |
| Neurological | Positive | Less burning in the right leg; no new weakness; no bladder or bowel control change |
| Psychiatric | Negative | Mood better; PHQ-9 score 6 with item 9 scored 0 |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Oxycodone 10 mg oral tablet, one tablet every 6 hours as needed for pain, no more than four a day (60 MME a day) | One tablet by mouth every 6 hours as needed for pain; no more than 4 tablets a day | Oral route | 2024-03-04 to 2026-10-15 | completed | S |
| Oxycodone 10 mg oral tablet, one tablet three times daily as needed for pain | One tablet by mouth three times daily as needed for pain | Oral route | 2026-10-15 | active | S |
| Oxycodone 5 mg oral tablet, one tablet at bedtime as needed for pain | One tablet by mouth at bedtime as needed for pain | Oral route | 2026-10-15 | active | S |
| Duloxetine 30 mg delayed-release oral capsule, one capsule daily | One capsule by mouth daily | Oral route | 2026-09-17 to 2026-10-01 | completed | S |
| Duloxetine 60 mg delayed-release oral capsule, one capsule daily | One capsule by mouth daily | Oral route | 2026-10-01 | active | S |
| Acetaminophen 500 mg oral tablet, two tablets three times daily | Two tablets by mouth three times daily; no more than 3,000 mg a day | Oral route | 2026-09-17 | active | S |
| Diclofenac sodium 1% topical gel, 2 g to the right ankle four times daily | Apply 2 g to the right ankle and foot four times daily | Topical route | 2026-09-17 | active | S |
| Cholecalciferol (vitamin D3) 2,000 units oral tablet, one tablet daily | One tablet by mouth daily | Oral route | 2026-09-17 | active | S |
| Naloxone 4 mg nasal spray, one spray into one nostril for suspected opioid overdose; may repeat in the other nostril | For suspected opioid overdose: one spray into one nostril and call 911; if there is no response after 2 to 3 minutes, give a second spray in the other nostril | Nasal route | 2026-09-17 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-15 | Body height | 160 | cm | S |
| 2026-10-15 | Body weight | 50.5 | kg | S |
| 2026-10-15 | Body mass index (BMI) [Ratio] | 19.7 | kg/m2 | S |
| 2026-10-15 | Systolic blood pressure | 114 | mm[Hg] | S |
| 2026-10-15 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-10-15 | Heart rate | 78 | /min | S |
| 2026-10-15 | Respiratory rate | 14 | /min | S |
| 2026-10-15 | Body temperature | 36.7 | Cel | S |
| 2026-10-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-15 | Mean score [PEG] | 6 | {score} | S | ||
| 2026-10-15 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S |
Vital signs recorded on 2026-10-15; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Alert and not sedated; pupils equal and normal in size |
| Lungs | Clear |
| Back | Lumbar paraspinal tenderness, unchanged |
| Right ankle | Bony enlargement and reduced motion; no effusion |
| Gait | Steadier with the cane and shoe lift |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Chronic low back and pelvic pain after remote spinal and pelvic fractures and spinal surgery, with neuropathic features in the right leg; linked to the documented 1925 injuries | active | confirmed | G89.21 | S — Synthetic modern diagnosis linked to the documented injuries; the neuropathic interpretation is R. |
| Post-traumatic osteoarthritis of the right ankle and foot after multiple leg fractures and a foot dislocation | active | confirmed | M19.171 | S — Synthetic diagnosis confirmed on the synthetic ankle X-ray. |
| Right leg weakness, atrophy, and shortening after childhood poliomyelitis; a congenital spinal anomaly has been proposed retrospectively | active | provisional | B91 | S — Synthetic modern coding of the documented childhood diagnosis; the alternative remains R. |
| Long-term opioid therapy for chronic pain, 60 MME a day at intake | active | confirmed | Z79.891 | S — Synthetic modern medication status; not a historical assertion. |
| Vitamin D deficiency | active | confirmed | E55.9 | S — Synthetic finding from the baseline 25-hydroxyvitamin D. |
| Acute viral upper respiratory infection (common cold), resolved without antibiotics | resolved | confirmed | J06.9 | S — Synthetic intercurrent illness at an unscheduled visit; it does not echo a documented illness. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PEG pain, enjoyment of life, and general activity score | Every visit | Completed today | 6.0, down from 7.3 at intake |
| Survey | PHQ-9 depression score, with item 9 | Every 2 to 4 weeks during active treatment | Completed today | 6, down from 8, with item 9 scored 0 |
| Medication safety | Opioid benefits and harms: function, sedation, constipation, falls | Every visit during a taper; at least every 3 months | Completed today | Function improving; no sedation, constipation, or falls |
| Medication safety | Taper step | About 10 percent a month for long-term therapy, adjusted to her response | Completed today | 60 to 52.5 MME a day, a 12.5 percent step, the smallest change possible with whole 5 mg tablets; agreed with her |
| Medication safety | Opioid withdrawal symptoms | At each contact after a reduction | Due | First check at next week's visit |
| Medication safety | Opioid use disorder assessment | Before tapering and whenever concerns arise | Completed today | No signs: one prescriber, a consistent urine drug test, no early refills or dose escalation |
| Medication safety | Prescription drug monitoring program check | Before each opioid prescription; at least every 3 months | Completed today | Checked before today's new prescription: a single prescriber and no sedatives |
| Laboratory | Urine drug test, with consent | Before long-term therapy, then at least annually | Up to date | At intake, consistent with the prescribed oxycodone only |
| Medication safety | Naloxone at home, with a family member trained | Offer when starting or continuing opioids; review each visit | Up to date | Confirmed at home and in date last week; reviewed again today |
| Medication safety | Concurrent benzodiazepines or other sedatives | Every visit | Completed today | None |
| Medication safety | Duloxetine tolerance after a dose change | About 2 weeks after each dose change | Completed today | No side effects on 60 mg; blood pressure 114/72 |
| Laboratory | ALT on regular acetaminophen | Periodically when acetaminophen approaches 3 g a day | Up to date | 22 U/L at intake; recheck at the six-week review |
| Examination | Right ankle examination: range of motion, effusion, alignment | Every visit | Completed today | Unchanged; no effusion |
| Imaging | Right ankle radiograph | Only for diagnostic uncertainty, clinical change, or surgical planning | Not indicated | No clinical change |
| Referral | Cognitive behavioral therapy for chronic pain | Weekly | Up to date | Weekly sessions start today |
| Self-management | Exercise program adherence | Every visit | Completed today | Physical therapy twice weekly, one session missed while ill; home exercises daily |
| Laboratory | 25-hydroxyvitamin D | About 3 months after starting repletion | Due | Recheck in about nine weeks |
| Medication safety | Influenza vaccine | Every season | Completed today | Given today |
Goal progress:
Immunizations given today: Influenza vaccine, 2026-2027 season [S]
Guideline basis: CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 (2022); Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians (2017); VA/DoD Clinical Practice Guideline for the Diagnosis and Treatment of Low Back Pain (2022); CMID: Clinical Monitoring Intelligence Database, osteoarthritis and depression monographs (2026)
Follow-up: Adult preventive visit next week, with a check for withdrawal. Six-week chronic pain review in two weeks. Next scheduled visit 2026-10-22: adult preventive visit. [S]